Physician profile
Bridget Wilson
NPI 1588429948
$4,496.39
in general payments reported to CMS, 2019-2025
29 companies · $2,671 in 2025
The $2,671 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,826 · 2025: $2,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,496.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $588.77 | 2024-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $545.85 | 2024-2025 | |
| Ferring Pharmaceuticals INC. | $364.02 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $338.16 | 2024-2025 | |
| Janssen Biotech, INC. | $301.97 | 2025 | Erleada, Carvykti, Rybrevant |
| Merck Sharp & Dohme LLC | $229.77 | 2024-2025 | Keytruda, Lynparza |
| Pfizer INC. | $207.62 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $203.24 | 2024-2025 | Gemtesa, Orgovyx |
| Teleflex LLC | $189.07 | 2024-2025 | Barrigel, Urolift |
| Blue Earth Diagnostics | $187.75 | 2025 | Posluma |
| Antares Pharma, INC. | $179.38 | 2024-2025 | Xyosted |
| Urogen Pharma, INC. | $176.66 | 2024-2025 | |
| Calyxo, INC. | $166.81 | 2025 | Cvac Aspiration System |
| Novartis Pharmaceuticals Corporation | $131.26 | 2024-2025 | |
| Axonics, INC. | $101.83 | 2024 | Bulkamid, Axonics |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $88.70 | 2024 | Gentlecath |
| Endo USA, INC. | $78.27 | 2024-2025 | Xiaflex, Aveed |
| Procept Biorobotics Corporation | $75.43 | 2024-2025 | Aquabeam System |
| Astellas Pharma US INC | $64.01 | 2024-2025 | Xtandi |
| Sun Pharmaceutical Industries INC. | $53.00 | 2024 | |
| Coloplast Corp | $45.75 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $37.71 | 2025 | |
| Davol INC. | $28.28 | 2024 | Channel Drain |
| Alnylam Pharmaceuticals INC. | $26.53 | 2025 | Givlaari |
| Endo Pharmaceuticals INC. | $24.96 | 2024 | Xiaflex |
| Inspire Medical Systems, INC. | $18.52 | 2025 | Inspire |
| Bioprotect Medical, INC. | $15.30 | 2025 | Bioprotect Balloon Implant System |
| Boston Scientific Corporation | $14.21 | 2025 | Ams 700 |
| Myriad Genetic Laboratories, INC. | $13.56 | 2024 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.